IP Verse

Crystal Form Of (R)-N-Methylnaltrexone Bromide And Uses Thereof - EP3263571

The patent EP3263571 was granted to Progenics Pharmaceuticals on Aug 23, 2023. The application was originally filed on Mar 28, 2008 under application number EP17172002A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3263571

PROGENICS PHARMACEUTICALS
Application Number
EP17172002A
Filing Date
Mar 28, 2008
Status
Patent Maintained As Amended
Jul 21, 2023
Grant Date
Aug 23, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ISARPATENTAug 10, 2020ISARPATENTWITHDRAWN

Patent Citations (23) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2005124657
DESCRIPTIONUS4719215
DESCRIPTIONUS4861781
DESCRIPTIONUS5102887
DESCRIPTIONUS5159081
DESCRIPTIONUS5250542
DESCRIPTIONUS5270328
DESCRIPTIONUS5434171
DESCRIPTIONUS5972954
DESCRIPTIONWO2006127899
OPPOSITIONEP2134718
OPPOSITIONUS4176186
OPPOSITIONUS60921111
OPPOSITIONWO02098422
OPPOSITIONWO2004043964
OPPOSITIONWO2004091622
OPPOSITIONWO2006127899
OPPOSITIONWO2008034973
OPPOSITIONWO2008109156
SEARCHUS4176186
SEARCHWO2004043964
SEARCHWO2004091623
SEARCHWO2006127899

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BAGNOL, D. ET AL., REGUL. PEPT, (1993), vol. 47, pages 259 - 273
DESCRIPTION- KOCH, T. R ET AL., DIGESTIVE DISEASES AND SCIENCES, (1991), vol. 36, pages 712 - 728
DESCRIPTION- REISINE, T.; PASTERNAK, G.; GOODMAN & GILMAN'S, The Pharmacological Basis of Therapeutics, 9th ed., (1996), pages 521 - 555
DESCRIPTION- SCHULLER, A.G.P. ET AL., SOCIETY OF NEUROSCIENCE ABSTRACTS, (1998), vol. 24, page 524
DESCRIPTION- YUAN, C. -S ET AL., DRUG AND ALCOHOL DEPENDENCE, (1998), vol. 52, page 161
OPPOSITION- A N Kotake, Et Al, "Variations in demethylation of N-methylnaltrexone in mice, rats, dogs and humans", Xenobiotica, (19890101), vol. 19, no. 11, pages 1247 - 1254
OPPOSITION- Chun-Su Yuan, Robert J Israel, "Expert Opinion on Investigational Drugs", Expert Opinion Investi. Drugs, (20060101), vol. 15, no. 5, pages 541 - 552, XP055733348
OPPOSITION- IORIO MARIA A; FRIGENI VIVIANA, "NARCOTIC AGONIST/ANTAGONIST PROPERTIES OF QUATERNARY DIASTEREOISOMERS DERIVED FROM OXYMORPHONE AND NALOXONE", European Journal of Medicinal Chemistry, Elsevier, Amsterdam, NL, NL, (19840101), vol. 19, no. 4, ISSN 0223-5234, pages 301 - 303, XP009072981
OPPOSITION- Joel Bernstein, "Chapter 7 Polymorphism of pharmaceuticals", Polymorphism in Molecular Crystals, Clarendon Press Oxford, (20020101), pages 240 - 256, XP055733354
OPPOSITION- FUNKE CAREL W; DE GRAAF JOOP S; BUURMAN EDWARD; THALEN HENK; VRIJHOF PIETER, "A PROTON AND CARBON-13 NUCLEAR MAGNETIC RESONANCE STUDY OF THREE QUATERNARY SALTS OF NALOXONE AND OXYMORPHONE", Journal of the chemical society , perkin transactions, CHEMICAL SOCIETY. LETCHWORTH., GB, GB, (19860101), doi:10.1039/p29860000735, ISSN 1472-779X, pages 735 - 738, XP009072982
OPPOSITION- A N Kotake, Et Al, "Variations in demethylation of N-methylnaltrexone in mice, rats, dogs and humans", Xenobiotica, (19890101), vol. 19, no. 11, pages 1247 - 1254, XP055733336

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents